Immunovant Inc (IMVT) — Defensive Interval Ratio

Latest as of December 2025: 9 days

Immunovant Inc (IMVT) has a Defensive Interval Ratio of 9 days as of December 2025. Defensive assets of $1.64 Million (cash $-, short-term investments $-, receivables $1.64 Million) cover 9 days of daily cash needs of $181.53K/day. Check Immunovant Inc (IMVT) tangible net worth to evaluate the tangible quality of the company's equity base.

Defensive Interval Ratio

9 days
Days of operational coverage

Defensive Assets

$1.64 Million
Cash + ST Investments + Receivables

Daily Cash Need

$181.53K
Current Liabilities ÷ 365

Current Liabilities

$66.26 Million
USD

Immunovant Inc Defensive Interval Ratio (2019–2025)

This chart shows how Immunovant Inc's Defensive Interval Ratio has evolved across 7 annual periods from 2019 to 2025. As of December 2025, the ratio stands at 9 days, meaning defensive assets of $1.64 Million can fund 9 days of operations without new revenue. Also explore net asset momentum of Immunovant Inc to track the company's year-over-year net asset growth rate.

Annual Defensive Interval Ratio for Immunovant Inc (2019–2025)

The table below presents the year-by-year Defensive Interval Ratio for Immunovant Inc from 2019 to 2025, covering 7 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see Immunovant Inc market cap and net worth.

Year DIR (days) Defensive Assets (USD) Daily Cash Need Cash ST Investments Change (days)
2025 13 days $2.51 Million $188.42K/day $- $- ▼ -28 days
2024 41 days $5.50 Million $133.17K/day $- $- ▲ +34 days
2023 7 days $885.00K $118.62K/day $- $- ▼ -98 days
2022 105 days $12.86 Million $121.97K/day $- $- ▲ +83 days
2021 22 days $1.14 Million $51.43K/day $- $- ▼ -50 days
2020 73 days $3.04 Million $41.97K/day $- $- ▼ -2769 days
2019 2842 days $2.96 Million $1.04K/day $- $-
DIR = (Cash + Short-term Investments + Net Receivables) / (Daily Cash Expenses)